GH1 and neoplasm: Treatment of the GH-secreting macroadenoma was initiated with lanreotide 120 mg once in 4 weeks, which resulted in no biochemical response (IGF-I level, 76.6 nmol/L and GH level, 28.0 μg/L) or inhibition of tumor growth after 4 doses.